NDAORALTABLET
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBUNOX is a fixed-dose combination tablet containing ibuprofen (a nonsteroidal anti-inflammatory drug) and oxycodone hydrochloride (an opioid analgesic), approved in 2004 for oral use. It combines peripheral anti-inflammatory action with central opioid analgesia for moderate-to-severe pain management. The product targets patients requiring both anti-inflammatory and opioid analgesia when used together.
LOE Approaching
With LOE approaching and limited clinical activity, the commercial team is likely in defense-and-transition mode rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMBUNOX offers minimal career growth potential given its LOE-approaching status and near-zero linked job openings; roles focus on managing decline rather than scaling growth. Professionals seeking dynamic career development should prioritize growth-stage or launch-phase products within the organization.
Brand ManagerField Sales Representative
Worked on COMBUNOX at Forest Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.